You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
柳藥股份(603368.SH):仙茱製藥取得藥品生產許可證
格隆匯 12-28 16:45

格隆匯12月28日丨柳藥股份(603368.SH)公佈,近日,公司全資子公司廣西仙製藥有限公司(“仙茱製藥)收到廣西壯族自治區藥品監督管理局核准簽發的《藥品生產許可證生產範圍:顆粒劑(含中藥配方顆粒)、中藥飲片(淨制、切制、煮制、炒制、蒸制、制、煅制)

仙茱製藥是公司旗下專門從事中藥配方顆粒生產研發的現代中藥創新企業,全面負責公司中藥配方顆粒生產研發中心項目的後期生產運營工作。該項目建設有中藥配方顆粒自動化生產車間、提取車間、質控及研發中心等,目前已完成200 餘個中藥配方顆粒產品的中試,涵蓋現有全部國標品種。此次取得藥品生產許可證後,仙茱製藥將全面開展產品備案工作,推動產品的正式生產上市。中藥配方顆粒生產研發項目的實施將進一步完善公司的中藥產業鏈,與中藥飲片、中成藥研發等形成產業互動,有利於提高公司中藥產品附加值,在當前國家鼓勵中藥創新和發展應用的政策背景下,依託公司成熟的營銷網絡渠道,加快自研中藥配方顆粒產品的市場覆蓋,增強公司整體盈利能力和市場競爭力。該項目短期內不會對公司經營業績產生重大影響從長期來看,將逐步形成公司新的利潤增長點,對公司生產經營產生積極影響

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account